STATCenter·
STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
Read at STAT →




